An investigation on behalf of investors in Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) shares over potential wrongdoing at Aevi Genomic Medicine, Inc. was announced and NASDAQ: GNMX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 05/11/2018 -- An investigation was announced for investors in shares of Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) concerning possible breaches of fiduciary duties by certain officers and directors at Aevi Genomic Medicine, Inc.
Investors who purchased shares of Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Aevi Genomic Medicine directors breached their fiduciary duties and caused damage to the company and its shareholders.
Wayne, PA based Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States.
Aevi Genomic Medicine, Inc reported that its Net Loss declined from $41.9 million in 2016 to $34.71 million in 2017.
Shares of Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) declined from $6.18 per share in March 2017 to as low as $0.98 per share in late May 2017.
On May 10, 2018, NASDAQ: GNMX shares closed at $1.49 per share.
Those who purchased shares of Aevi Genomic Medicine, Inc. (NASDAQ: GNMX), have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com